Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Lab test could match brain tumor patients to best drugs

NCT ID NCT06804655

First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 38 times

Summary

This study tests a method called pharmacoscopy, where a patient's tumor tissue is analyzed in the lab to find which drugs might work best for them. The goal is to see if this personalized approach is feasible for people with brain tumors that have not responded to standard treatments. About 40 adults with various refractory brain tumors will have their tumor samples tested, and results will guide their next treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cantonal Hospital St Gallen

    Sankt Gallen, Canton of St. Gallen, 9007, Switzerland

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University Hospital Basel

    Basel, Basel-Landschaft, 4021, Switzerland

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University Hospital Zurich

    Zurich, Canton of Zurich, 8091, Switzerland

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Pharmacoscopy (ex vivo drug profiling of tumor tissue to guide treatment selection)

What this could lead to

If successful, this approach could help doctors choose more effective drugs for individual patients with hard-to-treat brain tumors, potentially improving outcomes.

What could go wrong

This is a small early-phase trial (40 patients) focused on feasibility, not proof of effectiveness. The drug profiling may not always lead to a usable treatment, and benefits are uncertain.

Conditions

The condition(s) this trial relates to.

ependymoma glioblastoma glioma medulloblastoma meningioma neoplasm Neurologic Manifestations

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.